Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT01068210
Official study title

Lung Cancer Exercise Training Study

Study summary

The purpose of the study is look at the effects of different types of exercise training with a stretching group and its effect on lung cancer patients. Subjects will take part in a 16 week training intervention that can consist of aerobic, resistance, aerobic \& resistance, or a control group. Pre and Post testing will include stress tests, echos, blood, and urine samples.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedAerobic Training and Progressive Stretching

Plus 2 other study approaches.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 4, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
Memorial Sloan Kettering Cancer Center
Interventions being studied
Behavioral: Aerobic Training; Behavioral: Progressive Stretching; Behavioral: Resistance Training; Behavioral: Aerobic and Resistance Training
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Supportive or behavioral care→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Signed informed consent prior to initiation of study-related procedures
  • Age 21 - 80 years
  • Weight \< 205 kgs
  • ECOG ≤ 1
  • Diagnosed with histologically confirmed lung cancer, regardless of disease stage and receiving any prior line of any therapy in the context of metastatic disease
  • An interval of at least three months following the completion of primary resection, if appropriate
  • An interval of no longer than ten years following completion of primary therapy, if appropriate
  • Life expectancy ≥ 4 months
  • Performing less than 150 minutes of structured moderate-intensity or strenuous-intensity exercise per week
  • Exercise intolerance (i.e., patients must have a VO2peak below that predicted for active age and sex-matched individuals)
  • Willing to be randomized to one of the study arms
  • Willing to commit to the study program and comply with all related protocol procedures
  • Able to achieve an acceptable peak baseline CPET, as defined by any of the following criteria:
  • achieving a plateau in oxygen consumption, concurrent with an increase in power output;
  • a respiratory exchange ratio ≥ 1.10;
  • attainment of maximal predicted heart rate (HRmax) (i.e., within 10 bpm of age-predicted HRmax \[HRmax = 220-Age\[years\]);
  • volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale.
  • Able to complete an acceptable baseline CPET in the absence of high risk ECG findings or other inappropriate response to exercise as determined by the PI.
  • Ability to achieve and complete an acceptable baseline one-repetition maximum muscular strength test as defined by the effective execution of protocol-specific joint and muscle ranges of motion without remarkable signs or symptoms of pain, discomfort or distress.
Reasons someone may not be able to joinExclusion criteria
  • Presence of a concurrent, actively treated other malignancy, or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer);
  • Room air desaturation at rest ≤ 85%;
  • Mental impairment leading to inability to cooperate.
  • Any of the following absolute contraindications to cardiopulmonary exercise testing:
  • Acute myocardial infarction (within 3-5 days of any planned study procedures);
  • Unstable angina;
  • Uncontrolled arrhythmia causing symptoms or hemodynamic compromise;
  • Recurrent syncope;
  • Active endocarditis;
  • Acute myocarditis or pericarditis;
  • Symptomatic severe aortic stenosis;
  • Uncontrolled heart failure;
  • Acute (within 3 months) pulmonary embolus or pulmonary infarction;
  • Thrombosis of lower extremities;
  • Suspected dissecting aneurysm;
  • Uncontrolled asthma;
  • Pulmonary edema;
  • Respiratory failure;
  • Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Memorial Sloan Kettering Cancer CenterNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 4, 2025. Always confirm current availability with the study team.

View original record ↗